MiNA Therapeutics

MiNA Therapeutics: Versatile, proprietary small activating ribonucleic acid (saRNA) therapeutics platform and internal pipeline, initially focusing on oncology and rare disease indications, analogous to RNA Interference. Clinical proof of concept achieved in 2020 for first saRNA, with next study aimed at potential accelerated approval in 2024 Advancing 10 different saRNA assets (some in multiple indications) into the clinic by 2025. Preparing to initiate randomized Ph2 study for lead saRNA drug candidate MTL-CEBPA combined with sorafenib in second line hepatocellular carcinoma. Raised $30M Series A (Sep 2020). Current investors: aMoon, Golden Triangle Partners, Sosei, Galloway. Three pharma collaborations since Dec. 2019; $25M upfront from recent Lilly deal.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Investment Participation
Series A
Therapeutic Modalities
Platform Technology
84 Wood Lane
London, England W12 0BZ
United Kingdom

Company Participants at Spring Private Company Showcase

Robert Habib
MiNa Therapeutics, Chief Executive Officer
Robert joined MiNA as Chief Executive Officer in 2013. In that period he has been the driving force in establishing MiNA’s strategy, financing, and team of talented professionals. Prior to this Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.
Robin Wright
MiNa Therapeutics, CFO
Mr. Robin Wright serves as Chief Financial Officer at MiNA Therapeutics. Prior to MiNA Therapeutics he worked for Vaccitech Limited (2018-2021), Pharming Group N.V. (2020-2015), Family Company (2015-2014) and Imprimatur Capital Found Management (2014). Wright hold's his BA in Chemistry from University of Oxford.

Upcoming Company Event Participation